Hematopoietic cell transplantation: Progress and obstacles

Annals of Oncology

Volumn 18, Issue 9, 2007, Pages 1450-1456

  Devetten, M ^a   Armitage, J O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Allogeneic; Autologous; Stem cell transplantation

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BORTEZOMIB; BUSULFAN; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IMATINIB; LENALIDOMIDE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOABLATIVE AGENT; RETINOIC ACID; RITUXIMAB; THALIDOMIDE; THYMOCYTE ANTIBODY; TOSITUMOMAB I 131;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AZOOSPERMIA; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL RENEWAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE INFERTILITY; FOLLICULAR LYMPHOMA; GENE MUTATION; GENETIC RISK; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA TYPING; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE MYELOMA; MULTIPOTENT STEM CELL; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; OPTIMAL DRUG DOSE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; REDUCED INTENSITY CONDITIONING; REVIEW; STEM CELL MOBILIZATION; T CELL DEPLETION; UMBILICAL CORD BLOOD; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; GRAFT VS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; NEOPLASMS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 34548401754     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm064     Document Type: Review

References (73)

1. Thomas ED, Buckner CD, Banaji M et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511-533.
2. Thomas ED, Buckner CD, Clift RA et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 1979; 301: 597-599.
3. Clift R, Thomas ED. Follow-up 26 years after treatment for acute myelogenous leukemia. N Engl J Med 2004; 351: 2456-2457.
4. Jacobson LO, Simmons EL, Marks EK et al. The role of the spleen in radiation injury and recovery. J Lab Clin Med 1950; 35: 746-770.
5. Lorenz E, Uphoff D, Reid TR et al. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 1951; 12: 197-201.
6. Thomas ED. A history of bone marrow transplantation. In Blume K, Forman S, Appelbaum F (eds): Thomas' Hematopoietic Cell Transplantation, 3rd edition. Malden, MA: Blackwell Publishing 2004; 3-9.
7. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813-1826.
8. Osawa M, Hanada K, Hamada H et al. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 1996; 273: 242-245.
9. Dexter TM, Haemopoiesis in long-term bone marrow cultures. A review. Acta Haematol 1979; 62: 299-305.
10. Tse WT, Pendleton JO, Beyer WM et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 2003; 75: 389-397.
11. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of severe acute and extensive chronic graft-versus-host disease. Blood 2005; 106: 45a.
12. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997 3: 730-737.
13. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284.
14. Matthys P, Hatse S, Vermeire K et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol 2001; 167: 4686-4692.
15. Devine SM, Flomenberg N, Vesole DH et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1095-1102.
16. Flomenberg N, Devine SM, DiPersio JF et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-1874.
17. Roche V, Wagner JE Jr, Sobocinski KA et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 2000; 342: 1846-1854.
18. Rubinstein P, Carrier C, Scaradavou A et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339: 1565-1577.
19. Laughlin MJ, Eapen M, Rubinstein P et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265-2275.
20. Barker JN, Weisdorf DJ, DeFor TE et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105: 1343-1347.
21. Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325-3333.
22. Freedman AS, Gribben JG, Neuberg D et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780-2786.
23. Ladetto M, Zallio F, Vallet S et al. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/ immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia 2001; 15: 1941-1949.
24. Voso MT, Pantel G, Weis M et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 109: 729-735.
25. Vose JM, Bierman PJ, Enke C et al. Phase I trial of iodine-131 Tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 461-467.
26. Nademanee A, Forman S, Molina A et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005; 106: 2896-2942.
27. Press OW, Eary JF, Gooley T et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96: 2934-2942.
28. Epstein RB, Storb R, Ragde H et al. Cytotoxic typing antisera for marrow grafting in littermate dogs. Transplantation 1968; 6: 45-58.
29. Morishima Y, Sasazuki T, Inoko H et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002; 99: 4200-4206.
30. Petersdorf EW, Hansen JA, Martin PJ et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 2001; 345: 1794-1800.
31. Petersdorf EW, Gooley TA, Anasetti C et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998; 92: 3515-3520.
32. Hurley CK, Wagner JE, Setterholm MI et al. Advances in HLA: Practical implications for selecting adult donors and cord blood units. Biol Blood Marrow Transplant 2006; 12: 28-33.
33. Speiser DE, Tiercy JM, Rufer N et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 1996; 87: 4455-4462.
34. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
35. Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
36. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
37. Sandmaier BM, Maris MB, Maloney DG et al. Hematopoietic cell transplants (HCT) from HLA-matched related (MRD) and unrelated (URD) donors for patients with hematologic malignancies using low-dose TBI conditioning. Blood 2005; 106: 194a.
38. Giralt S, Thall PF, Khourl I et al. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
39. Ho AYL, Pagliuca A, Kenyon M et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004; 104: 1616-1623.
40. Kroger N, Bornhauser M, Ehninger G et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 2003; 82: 336-342.
41. Dasgupta RK, Rule S, Johnson P et al. Fludarabine phosphate and melphalan: A reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect. Bone Marrow Transplant 2006; 37: 455-461.
42. Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: A review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20: 1661-1672.
43. Aversa F, Terenzi A, Felicini R et al. Haploidentical stem cell transplantation for acute leukemia. Int J Hematol 2002; 76 (Suppl 1): 165-168.
44. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplant. Science 2002; 295: 2097-2100.
45. Devetten MP, Vose JM. Graft-versus-host disease: How to translate new insights into new therapeutic strategies. Biol Blood Marrow Transplant 2004; 10: 815-825.
46. Roche V, Franco RF, Porcher R et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 100: 3908-3918.
47. Lin MT, Storer B, Martin PJ et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003; 349: 2201-2210.
48. Holler E, Rogler G, Herfarth H et al. Both donor and recipient NOD2/ CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 2004; 104: 889-894.
49. Sakoda Y, Hashimoto D, Asakura S et al. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood 2006.
50. Fraser CJ, Bhatia S, Ness K et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: A report from the Bone Marrow Transplant Survivor Study. Blood 2006; 108: 2867-2873.
51. Pavletic SZ, Lee SJ, Socie G et al. Chronic graft-versus-host disease: implications of the National Institutes at Health consensus development project on criteria for clinical trials. Bone Marrow Transplant 2006; 38: 645-651.
52. Shapiro E, Kinsella TJ, Makuch RW et al. Effects of fractionated irradiation of endocrine aspects of testicular function. J Clin Oncol 1985; 3: 1232-1239.
53. Dann EJ, Epelbaum R, Avivi I et al. Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. Hum Reprod 2005; 20: 2247-2249.
54. Darrington DL, Vose JM, Anderson JR et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12: 2527-2534.
55. Kolb HJ, Socie G, Duell T et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999; 131: 738-744.
56. Andrykowski MA, Bishop MM, Hahn EA et al. Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. J Clin Oncol 2005; 23: 599-608.
57. Rizzo JD, Wingard JR, Tichelli A et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: Joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant 2006; 37: 249-261.
58. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
59. Blay J, Gomez F, Sebban C et al. The International Prognostic Index correlates to survival in patents with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group Blood 1998; 92: 3562-3568.
60. Villanueva M, Vose J. The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma. Clin Adv Hematol Oncol 2006; 4: 521-530.
61. Schouten HC, Qian W, Kvaloy S et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918-3927.
62. Brice P, Simon D, Bouabdallah R et al. High-dose therapy with autologous stemcell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patents included in the prospective GELF 86 protocol. Ann Oncol 2000; 11: 1585-1590.
63. Dreyling M, Lenz G, Hoster E et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network Blood 2005; 105: 2677-2684.
64. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
65. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
66. Burnett AK, Wheatley K, Goldstone AH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385-400.
67. Cassileth PA, Harrington DP, Appelbaum FR et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649-1656.
68. Suciu S, Mandelli F, de Witte T et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/ GIMEMAAML-10 trial. Blood 2003; 102: 1232-1240.
69. Hahn T, Wall D, Camitta B et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: An evidence-based review. Biol Blood Marrow Transplant 2006; 12: 1-30.
70. Baccarani M, Saglio G, Goldman J et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-1820.
71. Druker B, Guilhot F, O'Brien S et al. Long-term benefits of imatinib for patients with newly diagnosed chronic myelogenous leukemia in chronic phase: The 5-year update from the IRIS study. J Clin Oncol 2006; 24: 338s.
72. Bone Marrow Transplant: Despite Recruitment Successes, National Programs May be Underutilized. Washington, DC: General Accounting Office 2002. Document no. GAO-03-182.
73. Ho WL, Lin KH, Wang JD et al. Financial burden at national health insurance for treating patients with transfusion-dependent thalassemia in Taiwan. Bone Marrow Transplant 2006; 37: 569-574.